Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects
A Single Center, Randomized, Double-Blind, Active-controlled, Single-Dose, Phase I/II, Non-Inferiority Study Comparing ATGC-100 and Botox for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects
Sponsor: EuBiologics Co.,Ltd
A PHASE1/PHASE2 clinical study on Moderate to Severe Glabellar Lines, this trial is completed. The trial is conducted by EuBiologics Co.,Ltd and has accumulated 6 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 1 earlier version
-
Jul 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EuBiologics Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .